The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-04 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In women, the breasts overlie the pectoralis major muscles and extend on average from the level of the second rib to the level of the sixth rib in the front of the rib cage; thus, the breasts cover much of the chest area and the chest walls. At the front of the chest, the breast tissue can extend from the clavicle (collarbone) to the middle of the sternum (breastbone). At the sides of the chest, the breast tissue can extend into the axilla (armpit), and can reach as far to the back as the latissimus dorsi muscle, extending from the lower back to the humerus bone (the bone of the upper arm). As a mammary gland, the breast is composed of differing layers of tissue, predominantly two types: adipose tissue; and glandular tissue, which affects the lactation functions of the breasts. The natural resonant frequency of the human breast is about 2 hertz. Morphologically, the breast is tear-shaped. The superficial tissue layer (superficial fascia) is separated from the skin by 0.5–2.5 cm of subcutaneous fat (adipose tissue). The suspensory Cooper's ligaments are fibrous-tissue prolongations that radiate from the superficial fascia to the skin envelope. The female adult breast contains 14–18 irregular lactiferous lobes that converge at the nipple. The 2.0–4.5 mm milk ducts are immediately surrounded with dense connective tissue that support the glands. Milk exits the breast through the nipple, which is surrounded by a pigmented area of skin called the areola. The size of the areola can vary widely among women. The areola contains modified sweat glands known as Montgomery's glands.
With varying potencies ranging from high to low, it is a partial agonist of several of the serotonin 5-HT1 receptors, including the serotonin 5-HT1A, 5-HT1B, and 5-HT1D receptors, and is a partial agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. The drug also interacts with α2-adrenergic receptors, with the sigma σ1 and σ2 receptors, with the imidazoline I1 receptor, and with other targets. Along with the preceding receptor interactions, MDMA is a potent partial agonist of the rodent trace amine-associated receptor 1 (TAAR1). Conversely however, due to species differences, it is far weaker in terms of potency as an agonist of the human TAAR1. The drug appears to act as a weak partial agonist of the human TAAR1 rather than as an efficacious agonist. In relation to the preceding findings, MDMA has been said to be essentially inactive as a human TAAR1 agonist. TAAR1 activation is thought to auto-inhibit and constrain the effects of amphetamines that possess TAAR1 agonism, for instance MDMA in rodents. Elevation of serotonin, norepinephrine, and dopamine levels by MDMA is believed to mediate most of the drug's effects, including its entactogenic, stimulant, euphoriant, hyperthermic, and sympathomimetic effects. The entactogenic effects of MDMA, including increased sociability, empathy, feelings of closeness, and reduced aggression, are thought to be mainly due to induction of serotonin release.
=== Behavioral evidence === Fossils of the troodonts Mei and Sinornithoides demonstrate that some dinosaurs slept with their heads tucked under their arms. This behavior, which may have helped to keep the head warm, is also characteristic of modern birds. Several deinonychosaur and oviraptorosaur specimens have also been found preserved on top of their nests, likely brooding in a bird-like manner. The ratio between egg volume and body mass of adults among these dinosaurs suggest that the eggs were primarily brooded by the male and that the young were highly precocial, similar to many modern ground-dwelling birds. Some dinosaurs are known to have used gizzard stones like modern birds. These stones are swallowed by animals to aid digestion and break down food and hard fibers once they enter the stomach. When found in association with fossils, gizzard stones are called gastroliths.
The details of the Hill & Knowlton public relations campaign, including the incubator testimony, were published in John R. MacArthur's Second Front: Censorship and Propaganda in the Gulf War, and came to public attention when an Op-ed by MacArthur was published in The New York Times. This prompted a reexamination by Amnesty International, which had promoted an account alleging even greater numbers of babies torn from incubators than the fake testimony. After finding no evidence to support it, the organization issued a retraction. Bush repeated the incubator allegations on television. The Iraqi Army did commit well-documented crimes during its occupation, such as the summary execution without trial of three brothers, after which their bodies were stacked and left to decay in a street. Iraqi troops ransacked and looted private homes; one residence was repeatedly defecated in. A resident later commented: "The whole thing was violence for the sake of violence, destruction for the sake of destruction ... Imagine a surrealistic painting by Salvador Dalí". Bush repeatedly compared Saddam Hussein to Hitler.
=== Other === An engineer replaced a woodpecker-damaged feed horn of a high-power microwave antenna, a 15-meter dish at an Earth station of a television network, using a cherry picker. After finishing, he sent his technician to power up the transmitter, and attempted to lower the cherry picker down. The engine failed and the engineer was stuck next to the antenna, outside of its main lobe but well within the first sidelobe. The technician, unaware that the engineer was still close to the antenna, powered it up. The engineer was exposed to an intense microwave field for about three minutes, until the error was realized. There were no immediate symptoms; the next morning the engineer detected blood and solid matter in his urine, and visited a doctor, who found blood in stool and massive bowel adhesions. The engineer's medical problems lasted for many years.
Sources: en.wikipedia.org
== Instrumentation and Performance == Initially the digital ion trap was constructed in form of a 3D ion trap, where the drive signal was fed to the ring electrode of the trap. Instead of scanning up the RF voltage, in the DIT, the frequency of the rectangular waveform signal is scanned down during a forward mass scan. This avoided the high voltage breakdown which set the upper limitation of a mass scan. Mass range of DIT up to 18,000 Th was demonstrated by use of an atmospheric MALDI ion source and was later expanded to cover m/z of a singly charged antibody at about 900,000 Th by Koichi Tanaka etc. The MOSFET switch circuit is responsible to provide the rectangular wave drive signal. The drive circuit of DIT is much compact compared to the RF generator with LC resonator circuit used for conventional sinusoidal wave ion trap. It also provides the capability of fast start up and fast termination of the waveform, which enables injection and ejection of ion with high efficiency. A field adjusting electrode placed adjacent to the entrance end-cap and biased with certain dc voltages helped to achieve good mass resolution for both forward and reverse mass scans, as well as for precursor isolation. With trapping voltage of +/- 1kV, a zoom scan resolving power of 19,000 was demonstrated.
On 29 March, an Israeli airstrike targeting Aleppo International Airport killed 38 Syrian soldiers, seven Hezbollah fighters and seven militiamen, in what became the deadliest Israeli strike on Syria in the past three years. Another airstrike in Bazouriyeh, Lebanon killed Ali Abed Akhsan Naim, the deputy commander of Hezbollah's rocket and missiles unit who the IDF said was responsible for planning attacks against Israeli civilians. On 30 March, Reuters reported that an Israeli strike had injured three UN observers and a translator who were monitoring hostilities along the Blue Line. An investigation by the Lebanese Army determined that the explosion was caused by a landmine, which Israel said was planted by Hezbollah. The IDF struck a centre of the Lebanese Ambulance Association at the end of March killing seven paramedics.
Topical analgesia is generally recommended to avoid systemic side-effects. Painful joints, for example, may be treated with an ibuprofen- or diclofenac-containing gel (The labeling for topical diclofenac has been updated to warn about drug-induced hepatotoxicity.); capsaicin also is used topically. Lidocaine, an anesthetic, and steroids may be injected into joints for longer-term pain relief. Lidocaine is also used for painful mouth sores and to numb areas for dental work and minor medical procedures. In February 2007 the FDA notified consumers and healthcare professionals of the potential hazards of topical anesthetics entering the bloodstream when applied in large doses to the skin without medical supervision. These topical anesthetics contain anesthetic drugs such as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, or gel.
BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen. In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8-acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.
The FDA reviews commercially available test kits and their associated medical claims to ensure safety and efficacy before products are cleared or approved for use. The regulatory landscape for laboratory developed tests (LDTs) has been evolving significantly. On May 6, 2024, the FDA issued a final rule significantly modifying its approach to oversight of laboratory-developed tests, amending regulations to clarify that in vitro diagnostic products (IVDs) are devices under the Federal Food, Drug, and Cosmetic Act, including when manufactured by a laboratory. The final rule includes a policy under which FDA would phase out enforcement discretion for LDTs over a four-year period. The phaseout policy consists of five stages, starting May 6, 2024. DTC tests are specifically noted as having never been subject to enforcement discretion, meaning compliance with FDA requirements has always been expected for consumer-facing diagnostic tests. However, on April 17, 2025, a federal court blocked FDA's final rule on LDTs, creating uncertainty about the regulatory future. LDTs continue to be governed by CMS under CLIA oversight, but the long-term regulatory framework remains unsettled.
Sources: en.wikipedia.org
The Valve Index is a discontinued virtual reality headset created and manufactured by Valve. Announced on April 30, 2019, it was released on June 28 of the same year. The Index is a second-generation headset and the first to be fully manufactured by Valve. Half-Life: Alyx is bundled with the headset. In November 2025, Valve announced a successor, the Steam Frame, scheduled for launch in early 2026.
On 1 August 2024, the EU Artificial Intelligence Act entered into force, establishing the first comprehensive EU-wide AI regulation. In 2024, the Council of Europe created the first international legally binding treaty on AI, called the "Framework Convention on Artificial Intelligence and Human Rights, Democracy and the Rule of Law". It was adopted by the European Union, the United States, the United Kingdom, and other signatories. In a 2022 Ipsos survey, attitudes towards AI varied greatly by country; 78% of Chinese citizens, but only 35% of Americans, agreed that "products and services using AI have more benefits than drawbacks". A 2023 Reuters/Ipsos poll found that 61% of Americans agree, and 22% disagree, that AI poses risks to humanity. In a 2023 Fox News poll, 35% of Americans thought it "very important", and an additional 41% thought it "somewhat important", for the federal government to regulate AI, versus 13% responding "not very important" and 8% responding "not at all important". A 2026 NBC News Decision Desk poll powered by SurveyMonkey found that 52% of American adults used AI tools very often or sometimes, but only 18% said they could trust AI-generated information most or almost all of the time, and 70% were more worried than excited about AI. Polls in the United States found the main public concerns were job losses, impersonation, misinformation and information privacy.
== Applications == CagriSema is under investigation to treat type 2 diabetes and obesity. Preliminary trial results found a greater weight loss compared to either semaglutide or cagrilintide alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone. In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, comparable in efficacy to tirzepatide.
The resulting roGFP variants, named roGFP1-R1 through roGFP1-R14, are much more suitable for live-cell imaging. The roGFP1-R12 variant has been used to monitor redox potential in bacteria and yeast, but also for studies of spatially-organized redox potential in live, multicellular organisms such as the model nematode C. elegans. In addition, roGFPs are used to investigate the topology of ER proteins, or to analyze the ROS production capacity of chemicals.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.